Nov 6, 2025 4:05 pm EST Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Sep 17, 2025 4:05 pm EDT Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Sep 2, 2025 7:30 am EDT Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Aug 20, 2025 7:30 am EDT Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Jul 9, 2025 7:30 am EDT Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
